Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 39.18 0.00%
TEVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $45.70B
- P/E (TTM)
- 65.30
- Forward P/E
- 12.68
- EPS (TTM)
- $0.60
- Dividend yield
- None
- Ex-dividend date
- Nov 27, 2017
- 52-week range
- 18.83 – 40.79
- Day range
- 38.65 – 39.39
- Volume / Avg
- 3.46M / 5.34M
- Beta
- —
- Shares outstanding
- 1.17B
- Next earnings
- Nov 3, 2026
52-week range
TEVA stock today
On Oct 7, TEVA ended the session at $39.18, adding $0.05 (0.13%), versus the S&P 500's 0.22% decline. At this level, TEVA sits near the top of its 52-week range of $18.83 to $40.79: 3.9% below the high, set on Sep 21, 2026 and 108.1% above the low. TEVA is up 25.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 95.2%.
At 65.3x trailing earnings, Teva Pharmaceutical Industries trades above the peer-group median of 29.9x. Its forward P/E of 12.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Teva Pharmaceutical Industries's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Teva Pharmaceutical Industries
Company profileTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard D. Francis
- Headquarters
- Tel Aviv-Yafo
- Employees
- 31,173
- Website
- tevapharm.com
Financial highlights
Full financialsIn fiscal 2025, Teva Pharmaceutical Industries generated $17.26 billion in revenue, up 4.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.41 billion, for a net margin of 8.2% versus a median of -9.9% in the prior 5 years. Gross margin was 51.8% (up from 48.7%) and operating margin 12.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Growth | +4.32% | +4.40% | +6.17% | -6.00% | -4.69% |
| Net income | $1.41B | $-1.64B | $-559.00M | $-2.45B | $417.00M |
| EPS (diluted) | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$45.30+15.62%
- Strong buy 4
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.70
- Last reported (Q2 2026)
- Jul 29, 2026
- EPS actual vs est.
- $-0.49 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.085
- Ex-dividend date
- Nov 27, 2017
TEVA news
All TEVA news- iShares MSCI ACWI ex US ETF Experiences Big InflowNasdaqACWX, SPOT, TEVA, MSCI
- Teva's Ecopipam Shows Sustained Tic Reduction In Pediatric Tourette SyndromeNasdaq
- Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette SyndromeNasdaq
- Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13Nasdaq
- Teva and Samsung Bioepis partner on up to six biosimilarsSeeking Alpha
- Here's Why You Should Add URGN Stock to Your Portfolio NowNasdaqURGN, TEVA, ACIU, PGEN
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyNasdaqTEVA, SNY, AMRN, ACIU
- Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug TurnaroundNasdaq
Teva Pharmaceutical Industries peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs TEVA |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs TEVA |
| TAKTakeda Pharmaceutical Company Limited ADR | 18.37 | +1.49% | $58.68B | vs TEVA |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs TEVA |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs TEVA |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs TEVA |
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs TEVA |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs TEVA |
Indexes, lists and sector
Appears in lists
Teva Pharmaceutical Industries stock FAQ
What is Teva Pharmaceutical Industries's stock price today?
TEVA last traded at $39.18 as of Oct 7, 4:00 PM EDT, up 0.13% on the day. Prices are delayed at least 15 minutes.
Does Teva Pharmaceutical Industries pay a dividend?
Yes. Teva Pharmaceutical Industries pays $0.00 per share annually. The most recent dividend of $0.085 had an ex-dividend date of Nov 27, 2017.
When is Teva Pharmaceutical Industries's next earnings date?
Teva Pharmaceutical Industries is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.70.
What is TEVA's P/E ratio?
TEVA trades at a trailing P/E ratio of 65.30 and a forward P/E of 12.68, compared with a median of 29.9 for its closest peers.
Who is Teva Pharmaceutical Industries's CEO?
Mr. Richard D. Francis is the chief executive officer of Teva Pharmaceutical Industries Limited, which has about 31,173 employees.
Has TEVA ever split its stock?
Yes. The most recent TEVA stock split was a 2-for-1 split on Jul 1, 2004, one of 4 splits on record.
What is the TEVA 52-week high?
The 52-week high for TEVA is $40.79 and the 52-week low is $18.83. The stock is currently 3.9% below its high.